Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
This document is in .pdf format and can be downloaded at the bottom of this page.
In this issue:
Drug safety advice
-
Gadolinium-containing contrast agents and nephrogenic systemic fibrosis
-
Extraneal and products that contain (or are metabolised to) maltose, xylose, or galactose: false glucose reading
-
α1-adrenoreceptor antagonists and intraoperative floppy iris syndrome
-
Cabergoline: risk of cardiovalvulopathy
-
Linezolid: restriction of indication
-
Dopamine agonists and pathological gambling, increased libido, and hypersexuality
-
Antidepressants and risk of suicidal behaviour
Yellow Card scheme update
Hot topics
-
Isotretinoin for severe acne
-
Smoking-cessation aids
Stop press
- Recent letters to healthcare professionals
- Drug alerts
Other information from the MHRA
- Enforcement
- Advertising
- Consultations
Drug Safety Update: Volume 1, Issue 1, August 2007 
